Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 1134
Aptamer sequence: CTTACGACCCAGGGGGGTGGACAGGCGGGGGTTAGGGGGGTCGTAAG
Target unique ID: 16078
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_1080 THC1.2 Molecule Dronabinol 61 nM 20 mM Tris-HCl, 0.5 mM MgCl2, 20 mM NaCl, pH 7.4 33528997
Structure information of aptamer
Aptamer Sequence: CTTACGACCCAGGGGGGTGGACAGGCGGGGGTTAGGGGGGTCGTAAG
The optimal secondary structure in dot-bracket notation: ((((((((((.........(((........)))....))))))))))
The centroid secondary structure in dot-bracket notation: ((((((((((...........................))))))))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_1080 Description THC1.2
Aptamer chemistry DNA Length 47 nt
GC content 68.1% Molecular weight 14,787.44 Da
Molarity of 1 μg/μl solution 67.62 μM Number of G-quadruplexes 3
G-Score 58 Function Targeted binding
Sequence CTTACGACCCAGGGGGGTGGACAGGCGGGGGTTAGGGGGGTCGTAAG
Applications Binding to cannabinoids
Target information
Type Detail Type Detail
PubChem ID 16078 Molecular name Dronabinol
Molecular formula C21H30O2 Molecular weight 314.5
IUPAC name (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol InChIKey CYQFCXCEBYINGO-IAGOWNOFSA-N
LogP 5.736 Topological polar surface area 29.46
Hydrogen bond acceptor 2 Hydrogen bond donor 1

Synonym(s):
Dronabinol; TETRAHYDROCANNABINOL; Marinol; delta9-Tetrahydrocannabinol; delta9-THC; delta-9-tetrahydrocannabinol; 1972-08-3; Deltanyne; Abbott 40566; delta-9-THC; delta(9)-THC; Dronabinolum; THC; delta(1)-Tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta1-THC; 1-trans-delta-9-Tetrahydrocannabinol; delta(sup 1)-Thc; delta(sup 9)-Thc; Namisol; (-)-delta9-trans-Tetrahydrocannabinol; 9-tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; QCD 84924; SP 104; delta1-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; QCD-84924; Syndros; delta(sup 1)-Tetrahydrocannabinol; delta(sup 9)-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; .DELTA.9-Tetrahydrocannabinol; Cannabinol, delta1-tetrahydro-; CCRIS 4726; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; CHEBI:66964; 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; .DELTA.1-THC; .DELTA.9-THC; CHEMBL465; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol; UNII-7J8897W37S; Cannabinol, 1-trans-delta(sup 9)-tetrahydro-; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 7J8897W37S; NSC-134454; Dronabinolum [Latin]; Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo(b,d)pyran-1-ol; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; (-)-.DELTA.9-THC; Compassia; Relivar; (L)-.delta.1-Tetrahydrocannabinol; (-)-.DELTA.1-Tetrahydrocannabinol; (-)-.DELTA.9-Tetrahydrocannabinol; L-.delta.1-trans-Tetrahydrocannabinol; L-trans-.delta.9-Tetrahydrocannabinol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; 6H-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)-; (-)-.DELTA.9-trans-Tetrahydrocannabinol; (-)-trans-.DELTA.9-Tetrahydrocannabinol; Marinol (TN); DEA No. 7369; delta1-Tetrahydrocannabinol (VAN); delta9-Tetrahydrocannabinol (VAN); Dronabinol (USP/INN); .DELTA.1-Tetrahydrocannabinol; Tetrahydrocannabinol delta9; (-)-trans-Delta9-THC; (l)-delta(sup 1)-Tetrahydrocannabinol; Cannabinol, .DELTA.1-tetrahydro-; 1-trans-delta(sup 9)-Tetrahydrocannabinol; .DELTA.9-trans-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; L-.delta.1-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; delta9-trans-Tetrahydrocannabinol; HSDB 6471; trans-delta9-Tetrahydrocannabinol; (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; CAT-310; 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; L-trans-delta9-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; 6465-30-1; 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; DRG-0138; 14C-.DELTA.1-Tetrahydrocannabinol; trans-.DELTA.9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-delta9-Tetrahydrocannabinol; NSC 134454; .delta.-9-THC; 1-trans-delta(sup9)-tetrahydrocannabinol; .delta.(sup9)-THC; 3ls4; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; 1-trans-.delta.(sup9)-tetrahydrocannabinol; DSSTox_CID_1327; (-)-.delta.(sup9)-trans-Tetrahydrocannabinol; Epitope ID:224552; SCHEMBL4609; delta 9-Tetrahydrocannabinol; delta-9 Tetrahydrocannabinol; DSSTox_RID_76083; trans-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; DSSTox_GSID_21327; BIDD:GT0427; Dronabinol [USAN:USP:INN]; .delta.-9-tetrahydrocannabinol; ABBOTT-40566; GTPL2424; Cannabinol, tetrahydro- (6CI); DTXSID6021327; BDBM60994; J882F; US9416103, Delta9-THC; INT-0010; ZINC1530625; Tox21_112616; BDBM50007391; NSC134454; PDSP2_000714; SP-104; Cannabinol, Delta1-tetrahydro- (7CI); DB00470; INT-0010/06; (-)-Delta9-Tetrahydrocannabinol solution; CAS-1972-08-3; Synthetic THC in sesame oil / soft gelatin; C06972; Cannabinol, 1-trans-.delta.(sup9)-tetrahydro-; D00306; Tetrahydrocannabinols (-)-trans-.delta.9-form; Dronabinol in sesame oil in soft gelatin capsule; Q190067; (-)-Delta9-THC (Dronabinol) 0.1 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 1.0 mg/ml in Methanol; (-)-Delta9-THC (Dronabinol) 5.0 mg/ml in Methanol; Delta9-Tetrahydrocannabinol solution, ethanol solution; Delta9-Tetrahydrocannabinol 250 microg/mL in Acetonitrile; UNII-K4H93P747O component CYQFCXCEBYINGO-IAGOWNOFSA-N; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 100 microg/mL in Methanol; (-)-Delta9-Tetrahydrocannabinol (Delta9-THC) 1000 microg/mL in Methanol; 6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-; (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol(l)-delta(sup 1)-Tetrahydrocannabinol; (10R,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; (6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6H,6AH,7H,8H,10AH-BENZO[C]ISOCHROMEN-1-OL; (S)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(DeltaE-9-THC); 6H-Dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-; Delta-9-Tetrahydrocannabinol, United States Pharmacopeia (USP) Reference Standard; (-)-Delta9-Tetrahydrocannabinol solution, ~1 mg/mL in ethanol, analytical standard, for drug analysis; (-)-trans-Delta9-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol(delta9-THC(delta9-tetrahydrocannabinol)); 8,8-Dimethyl-11-methylene-5-pentyl-3,4,8a,9,10,11,12,12a-octahydro-2H,8H-1,7-dioxa-benzo[c]phenanthrene; Delta9-Tetrahydrocannabinol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis

Activity data
Interaction ID 1134
Target type Molecule
Target unique ID 16078
Activity 61 nM
Binding Conditions/Buffer

20 mM Tris-HCl, 0.5 mM MgCl2, 20 mM NaCl, pH 7.4
Assay

Characterization of the ligand-binding affinity of THC1.2 using ITC
PubMed ID 33528997
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_1081 DNA CTTACGACTGTGGTCGGGTGGTGGGCCTCTAGAGGGGTGTCGTAAG 65.96%
Apta_831 DNA CCGCCCAGCGGGGGTAGGGCCGGACGTAGGAGGAGCTGCG 59.57%
Apta_1087 DNA CTTACGACTCAGGCATTTTGCCGGGTAACGAAGTTACTGTCGTAAG 59.57%
Apta_478 DNA CTTCACTTTCGTGGACGGTGGCGTCGGGGCGGTTTGTATG 57.45%
Apta_988 DNA AAGGATGACTGACGACGATGGGAATGGAGAGGAAGGGGATATAGGTATGTTGGATGTAG 55.93%
Apta_488 DNA CGACCAGGGTGGGAGGGGGACGGGCTGGCGGCGCGCGGTAATG 55.32%
Apta_649 DNA GCACACCGATGGCGGTCCTGTTTAGGGGGTGTGCGTG 55.32%
Apta_666 DNA TCGACCTCGCGCGAGGAGGGTGGAGGGTCGTAGAGCGCGTA 55.32%
Apta_750 DNA ATGCGAACAGGTGGGTGGGTTGGGTGGATTGTTCGGCTTCTTGAT 55.32%
Apta_869 DNA ACTAGGACGCTTGGGAGGGGGGGTGGGGTGTCCGGTCGCG 55.32%
Apta_1189 DNA GCGGGCGGGGGGAGGGCGGCCGTGGGCTGCGAGTGGGAGG 55.32%
Apta_1190 DNA TTCAGGGCGGGGTAAACGGGAGGTGGGGGGGGCTTGGGAC 55.32%
Apta_1259 DNA GGCGCGGCATGGTGTGGACTCCAGGCGGTAGGGATGTCGT 55.32%
Apta_223 DNA CATTGAGATAGCTAGTTGTAGCTGCGTCATAGGCTGGGTTGGGTCTAGTGGTTGGGTGTG 55.00%
Apta_79 DNA ATCTCGAGTCATAGGGGGCGCGAACATACGCGGTTGGTGTGGTTGGCTGACTCGT 54.55%
Apta_1116 DNA CGTACGGAATTCGCTAGCCGGGGTGGGAACCAGTCTTGCGCGGGTGACGGATCCGAGCTCCACGTG 54.55%
Apta_651 DNA CCTGCACCTCGTCCAGCATGCACACCGATGGCGGTCCTGTTTAGGGGGTGTGCGTG 53.57%
Apta_1230 DNA GGCGATAGGCAGTGTTGCGGGGTCGGAGAGCGAGGTAATAGCGTGTATGGGTGCTGTGTG 53.33%
Apta_47 DNA GACCTAGCAGTGGACATGTGGCAGGGTGAAGTGGCATCGTC 53.19%
Apta_65 DNA CTACCGTGGTAGGGAAGGTTGGAGTGTAG 53.19%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43983
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.